Jefferies Group Reiterates “€80.00” Price Target for Sanofi (SAN)
SAN has been the subject of several other research reports. Morgan Stanley set a €92.00 ($109.52) target price on Sanofi and gave the stock a buy rating in a research note on Friday, October 6th. Goldman Sachs Group set a €82.00 ($97.62) target price on Sanofi and gave the stock a neutral rating in a research note on Friday, November 3rd. set a €78.00 ($92.86) target price on Sanofi and gave the stock a neutral rating in a research note on Friday, November 3rd. UBS Group set a €82.00 ($97.62) target price on Sanofi and gave the stock a neutral rating in a research note on Monday, October 23rd. Finally, Deutsche Bank set a €96.00 ($114.29) target price on Sanofi and gave the stock a buy rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of €87.06 ($103.65).
Shares of Sanofi (EPA SAN) traded down €0.39 ($0.46) during midday trading on Tuesday, reaching €73.01 ($86.92). The company’s stock had a trading volume of 1,350,000 shares, compared to its average volume of 2,340,000. The firm has a market capitalization of $92,220.00 and a P/E ratio of 20.22. Sanofi has a 12-month low of €71.06 ($84.60) and a 12-month high of €92.97 ($110.68).
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/01/17/jefferies-group-reiterates-80-00-price-target-for-sanofi-san.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.